Mouse models of Ebola virus tolerance and lethality: characterization of CD-1 mice infected with wild-type, guinea pig-adapted, or mouse-adapted virus
Antiviral Research, ISSN: 0166-3542, Vol: 210, Page: 105496
2023
- 3Citations
- 12Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations3
- Citation Indexes3
- CrossRef2
- Captures12
- Readers12
- 12
- Mentions1
- News Mentions1
- 1
Most Recent News
New Ebola Virus Findings from Viral Special Pathogens Branch Discussed (Mouse Models of Ebola Virus Tolerance and Lethality: Characterization of Cd-1 Mice Infected With Wild-type, Guinea Pig-adapted, or Mouse-adapted Virus)
2023 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Data detailed on Viral Hemorrhagic Diseases and Conditions -
Article Description
Development of lethal models of Ebola virus disease has been achieved by the serial passage of virus isolates from human cases in mice and guinea pigs. Use of mice infected with non-adapted virus has been limited due to the absence of overt clinical disease. In recent years, newly recognized sequelae identified in human cases has highlighted the importance of continued investigations of non-lethal infection both in humans and animal models. Here, we revisit the use of rodent-adapted and non-adapted Ebola virus (EBOV) in mice to investigate infection tolerance and future utility of these models in pathogenesis and therapeutic intervention studies. We found that like non-adapted wild-type EBOV, guinea pig-adapted EBOV resulted in widespread tissue infection, variably associated with tissue pathology, and alterations in clinical and immunological analytes in the absence of overt disease. Notably, infection with either non-lethal variant did not greatly differ from lethal mouse-adapted EBOV until near the time end-point criteria are reached in these mice. These data support future investigations of pathogenesis, convalescence, and sequelae in mouse models of virus tolerance.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0166354222002650; http://dx.doi.org/10.1016/j.antiviral.2022.105496; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85146453194&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36567020; https://linkinghub.elsevier.com/retrieve/pii/S0166354222002650; https://dx.doi.org/10.1016/j.antiviral.2022.105496
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know